Key result
Rhodiola wallichiana targets VEGFA and MAPK1 pathways to potentially treat angina pectoris.
Why the study?
Rhodiola wallichiana var. cholaensis (RW) is used to treat angina pectoris, but its underlying mechanisms remain unclear.
This computational study provides a theoretical framework for the multitarget mechanisms of Rhodiola wallichiana var. cholaensis in angina pectoris, identifying key molecular targets and pathways for future experimental validation.
These computational predictions for Rhodiola in angina are hypothesis-generating; should not change practice pending experimental validation.
Background: (RW) is one of the traditional Chinese medicinal materials, which is used to treat angina pectoris (AP). However, the possible underlying mechanisms remains unclear. The aim of this study was to explore RW in the treatment of AP and to identify the potential mechanism of the core compounds. Methods: In this study, systematic and comprehensive network pharmacology and molecular docking were used for the first time to explore the potential pharmacological mechanisms of RW on AP. First, the relative compounds were obtained by mining the literature, and potential targets of these compounds using target prediction were collected. We then built the AP target database using the DigSee and GeneCards databases. Based on the data, overlapping targets and hub genes were identified with Maximal Clique Centrality (MCC) algorithm in Cytoscape, cytoHubba. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and protein-protein interaction (PPI) analysis were performed to screen the hub targets by topology. Molecular docking was utilized to investigate the receptor-ligand interactions on Autodock Vina and visualized in PyMOL. Results: ) mainly involved in the complex treatment effects associated with the protection of the vascular endothelium, as well as the regulation of glucose metabolism, cellular processes, inflammatory responses, and cellular signal transduction. Molecular docking indicated that the core compounds had good affinity with the core targets. Conclusions: The results of this study preliminarily identify the potential targets and signaling pathways of RW in AP therapy and lay a promising foundation for further experimental studies and clinical trials.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied Angina pectoris. Rhodiola wallichiana var. cholaensis (RW) active compounds was evaluated on Potential pharmacological targets and signaling pathways. Network pharmacology and molecular docking predicted that Rhodiola wallichiana var. cholaensis treats angina pectoris by regulating nine core targets (including VEGFA and MAPK1) and associated signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: